Search Results

You are looking at 41 - 50 of 131 items for :

  • "symptom burden" x
  • Refine by Access: All x
Clear All
Full access

Palliative Care: Who is Responsible?

Amanda M. Rosenblum and Martin R. Chasen

interdisciplinary specialist palliative care in reducing symptom burden and detecting distress in patients with high intensity scores. Their team consistently used 2 validated tools at patient encounters: the Edmonton Symptom Assessment System (ESAS) and the

Full access

Validating a Patient-Reported Outcomes–Derived Algorithm for Classifying Symptom Complexity Levels Among Patients With Cancer

Linda Watson, Siwei Qi, Andrea DeIure, Eclair Photitai, Lindsi Chmielewski, and Louise Smith

Background For patients with cancer, experiencing multiple concurrent symptoms is common. 1 – 4 This concept has been described in a variety of ways, such as symptom clusters, symptom burden, or complex symptoms. Although these terms have similar

Full access

Impact of Psychological Distress on Treatment Timeliness in Oncology Patients at a Safety-Net Hospital

Sheshadri Madhusudhana, Michelle Gates, Daulath Singh, Punita Grover, Mahathi Indaram, and An-Lin Cheng

poorer survival, this likely reflects the preferential initiation of immediate treatment for patients with poorer prognoses and greater symptom burden at diagnosis, such as in the case of advanced lung cancer. 7 , 8 Previous research on treatment

Full access

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Aaron T. Gerds, Jason Gotlib, Haris Ali, Prithviraj Bose, Andrew Dunbar, Amro Elshoury, Tracy I. George, Krishna Gundabolu, Elizabeth Hexner, Gabriela S. Hobbs, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Animesh Pardanani, Nikolai Podoltsev, Lindsay Rein, Rachel Salit, Brady L. Stein, Moshe Talpaz, Pankit Vachhani, Martha Wadleigh, Sarah Wall, Dawn C. Ward, Mary Anne Bergman, and Cindy Hochstetler

However, certain aspects of clinical management regarding the diagnosis, assessment of symptom burden, and selection of appropriate symptom-directed therapies continue to present challenges for hematologists and oncologists. 11 Molecular

Full access

Implementing Routine Screening for Distress, the Sixth Vital Sign, for Patients With Head and Neck and Neurologic Cancers

Barry D. Bultz, Amy Waller, Jodi Cullum, Paula Jones, Johan Halland, Shannon L. Groff, Catriona Leckie, Lisa Shirt, Scott Blanchard, Harold Lau, Jacob Easaw, Konrad Fassbender, and Linda E. Carlson

Cancer Centre. Although these clinics are relatively small, patients often report high levels of symptom burden, needs, and concerns. 16 , 17 Few studies have examined the benefits of psychosocial interventions in these tumor groups. 16 , 17 The current

Full access

Palliative Care, Version 1.2014

Michael H. Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Susan Block, Shirley N. Codada, Shalini Dalal, Maria Dans, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Todd M. Sauer, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Carin Van Zyl, Sharon M. Weinstein, Mary Anne Bergman, and Jillian L. Scavone

of NCCN®. Palliative care has been shown to reduce symptom burden, improve quality of life, and increase the odds of dying at home. In a recent study comparing standard care with ongoing palliative care in patients with advanced cancer and a

Full access

Integrating Palliative Care in Pediatric Oncology: Evidence for an Evolving Paradigm for Comprehensive Cancer Care

Deena R. Levine, Liza-Marie Johnson, Angela Snyder, Robert K. Wiser, Deborah Gibson, Javier R. Kane, and Justin N. Baker

were significant differences in the use of PC among various clinical services, which suggested that symptom burden was underestimated in certain diagnostic groups. 17 Although the underestimation of symptom burden and underutilization of PC services

Full access

Asking “How Are You?”

Stewart B. Fleishman

intended to become a symptom-burden or quality-of-life assessment tool. Because the committee members each had day jobs, and funding for such a nascent program was limited from within NCCN and extramurally, it took many meetings and lots of compromise and

Full access

The Need for United States–Based Guidelines for Myeloproliferative Neoplasms

Brady L. Stein, Susan O’Brien, Peter Greenberg, and Ruben A. Mesa

symptom burden is increasing, and accordingly, focus on symptom-directed therapy, which served as a basis for approval of JAK inhibitors, is also increasing. An MPN guideline can emphasize the need for symptom assessment when planning therapy, and outline

Full access

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A. M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar

development of targeted therapies, which have resulted in significant improvements in disease-related symptoms and quality of life. 7 , 8 However, certain aspects of clinical management regarding diagnosis, assessment of symptom burden, and selection of